sebetralstat (Ekterly)

Indications

• on-demand oral treatment for hereditary angioedema (FDA-approved)

Dosage

• 600 mg (2 tablets) orally at the earliest recognition of an attack

Adverse effects

• headache >= 2%

Drug interactions

• strong CYP3A4 inhihitors: avoid oncomitant use
• moderate CYP3A4 inhihitors:
  • 300 mg (one tablet) orally at earliest recognition of an attack
  • a 2nd dose of 300 mg may be taken at >=3 hours after 1st dose if response is inadequate or if symptoms worsen
• weak CYP3A4 inhihitors: no dosage reduction indicated
• strong & moderate CYP3A4 inducers: avoid oncomitant use
• weak CYP3A4 inducers: no dosage reduction indicated

• drug interaction(s) of methotrexate with biological response modifier

Mechanism of action

• oral plasma kallikrein inhibitor in adults & adolecents >= 12 years

Notes

• $16,720 per dose

More general terms

• biological response modifier